Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Ho, Anthony Dick [VerfasserIn]   i
 Hensel, Manfred [VerfasserIn]   i
Titel:Pentostatin for the treatment of indolent lymphoproliferative disorders
Verf.angabe:Anthony D. Ho and Manfred Hensel
E-Jahr:2006
Jahr:[2006]
Umfang:9 S.
Fussnoten:Gesehen am 22.11.2021
Titel Quelle:Enthalten in: Seminars in hematology
Ort Quelle:Philadelphia, Pa. : Saunders, 2000
Jahr Quelle:2006
Band/Heft Quelle:43(2006), Seite S2-S10
ISSN Quelle:1532-8686
Abstract:Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials with pentostatin used high doses for acute lymphoblastic leukemias, which were characterized by high levels of ADA. Through the efforts of a few investigators, low-dose regimens that are active and well tolerated for indolent lymphoid malignancies have been developed. Myelosuppressive adverse effects have been shown to be minimal using these schedules. Lymphoplasmacytic lymphoma (LL) is an indolent chronic B-cell lymphoproliferative disorder moderately responsive to alkylating agents. All of the purine analogues have shown activity in LL. However, the advantage of pentostatin over the other agents is the relatively specific toxicity to lymphoid cells and the paucity of myelosuppression as a single agent. No direct comparisons of the agents have been investigated, although pentostatin may be considered to be preferred since it has not been associated with toxicity to myeloid progenitors in colony assays. This is of significance for patients who might benefit from high-dose chemotherapy with autologous stem cell transplantation.
DOI:doi:10.1053/j.seminhematol.2005.12.005
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1053/j.seminhematol.2005.12.005
 Volltext: https://www.sciencedirect.com/science/article/pii/S0037196305002623
 DOI: https://doi.org/10.1053/j.seminhematol.2005.12.005
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1778266355
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68803991   QR-Code
zum Seitenanfang